How to seek launch excellence in China

16 January 2019

China may offer a dynamic market for drug companies, but the country’s changeable policies and unique healthcare insurance system are among the major challenges faced by companies seeking launch excellence, reports The Pharma Letter’s local correspondent, Wang Fangqing.

What could be the proper approach? In short, plan early and have vision, according to Zhu Liliang, director of management consulting at IQVIA.

“Planning should start as early as in the pre-clinical stage. Some key points you have to think over include the indications, your target, and your stakeholders,” Ms Zhu said.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK